Values as of: 2025-05-29
COMMON STOCK | Biotechnology |
Last Closing
USD 0.0001Change
0.00 (0.00)%Market Cap
USD 0.07BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 34.32B |
| UCBJY | UCB SA ADR |
+2.52 (+2.85%) |
USD 33.77B |
| UCBJF | UCB SA |
+3.64 (+2.07%) |
USD 33.01B |
| WXIBF | WuXi Biologics |
N/A |
USD 12.07B |
| WXXWY | WuXi Biologics (Cayman) Inc |
-0.14 (-2.10%) |
USD 12.07B |
| GNMSF | Genmab A/S |
-2.00 (-0.95%) |
USD 12.01B |
| IVBIY | IVBIY |
N/A |
USD 11.04B |
| AKESF | Akeso, Inc. |
-0.45 (-4.14%) |
USD 9.60B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 9.28B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 8.94B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| QCLN:F | First Trust Nasdaq Clean .. | 7.41 % | 0.00 % |
N/A |
N/A |
| QCLN:XETRA | First Trust Nasdaq Clean .. | 7.41 % | 0.00 % |
-0.13 (-0.57%) |
N/A |
| QCLN:LSE | First Trust Nasdaq Clean .. | 7.20 % | 0.00 % |
-11.85 (-0.57%) |
USD 0.01B |
| QCLU:LSE | First Trust Nasdaq® Clea.. | 7.20 % | 0.00 % |
-0.18 (-0.57%) |
USD 0.01B |
| USTP:XETRA | Ossiam US Steepener UCITS.. | 6.50 % | 0.00 % |
+0.26 (+-0.57%) |
N/A |
| DRUP:F | Lyxor Index Fund - Lyxor .. | 1.83 % | 0.00 % |
-0.08 (-0.57%) |
N/A |
| MIDF | 1.54 % | 0.00 % |
N/A |
N/A | |
| IXN | iShares Global Tech ETF | 0.00 % | 0.46 % |
-0.37 (-0.57%) |
N/A |
| XSD | SPDR® S&P Semiconductor .. | 0.00 % | 0.35 % |
-5.91 (-0.57%) |
N/A |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -99.50% | 3% | F | N/A | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -99.50% | 3% | F | N/A | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -99.75% | 5% | F | 1% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -99.75% | 5% | F | 1% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -99.92% | 15% | F | 3% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -99.92% | 15% | F | 3% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 754.74% | 90% | A- | 95% | A | ||
| Dividend Return | 754.74% | 90% | A- | 95% | A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 3,026.49% | 12% | F | 5% | F | ||
| Risk Adjusted Return | 24.94% | 83% | B | 65% | D | ||
| Market Capitalization | 0.07B | 72% | C | 55% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
